Glucocorticoid or androgen for autoimmune premature ovary failure in mice
- VernacularTitle:糖皮质激素或雄激素治疗自身免疫性卵巢早衰小鼠
- Author:
Xiaobo SHI
;
Na LI
;
Can LIAO
;
Qing SHU
;
Fufan ZHU
- Publication Type:Journal Article
- Keywords:
premature ovary failure;
autoimmune diseases;
therapy;
glucocorticoid;
an-drogen
- From:
Journal of Central South University(Medical Sciences)
2009;34(7):576-581
- CountryChina
- Language:Chinese
-
Abstract:
Objective Using mouse autoimmune premature ovary failure (POF) model to seek theoretical evidence for a possible clinical therapy of autoimmune POF with glucocorticoid (GC) or an-drogen. Methods After autoimmune POF was induced in 60 mice by Pzp3, the mice were randomly as-signed into 3 groups (n=20) : Two groups were treated with GC or androgen and the control group was treated with distilled water. We observed the changes in the sexual cycles of the mice, the serum level of AzpAb, infiltration of cells positively expressing CD45 in the ovary, and pathological alterations of the ovary. Results The sexual cycle of each therapy group was significantly different from that of the control group. The mean serum level of AzpAb of each therapy group was significantly lower than that of the con-trol group, and the mean serum level of AzpAb in the GC group was significantly higher than that of the androgen group. The percentage of growing follicles in the ovary of each therapy group was significantly higher than that of the control group. Ovaries infiltrated by cells positively expressing CD45 of each thera-py group were significantly fewer than those of the control group. Conclusion GC or androgen in mice with autoimmune POF could obviously ameliorate the pathogenetic conditions of the disorder, and both treatments have similar therapeutic efficacy.
